The outcome of the five-year test showed the progression of nearsightedness could slow down by around 50 percent, and are a safe firstline defense against the rapidly expanding epidemic of nearsightedness in children.
Recently, in the US around 42 percent of the people is myopic, a huge jump from your 25 percent that have been shortsighted while in the ’70s. In developed parts of asia, the costs are as large as 80 and 90-percent among teenagers.
Although the vision may be adjusted with glasses, contacts, and surgery, in serious cases the situation can lead to retinal detachment as well as premature cataracts.
Nevertheless the new study implies that eye-drops containing 0.01 percent of the treatment generally known as atropine, could slow down the progression of the illness down.
Atropine is often used to deal with lazy eyes and has been shown to have some benefits when it comes to shortsightedness, as it inhibits axial growth of the eye, which is associated with myopia. But no long-term studies had been completed on how to best use the drops, and doctors are wary of them due to potential side effects.
According to lead researcher Donald T. Tan, an ophthalmologist from the Singapore Eye Research Institute and the National Singapore Eye Centre,
For a long time we’ve known that atropine drops can help keep myopia from getting worse to some degree. We now have data showing that it is not only effective, but also safe.”
After the first two years, the children stopped taking the medication for 12 months while their vision continued to be tested. The researchers noticed that the vision of those given the stronger dose eye drops had become more myopic during that year off, so they gave those children the 0.01 percent dose of drops for another two years.
The results, presented in the Academy of Ophthalmology’s annual meeting this week, were striking: following the five decades, their peers were not much less myopic than children who had utilized the low dose drops, and the researchers suggest that the benefits of the medication outweigh these risks.
The drops also appeared protected for all the participants to utilise throughout the length of the study, and compared to an earlier study on the untreated progression of myopia, the team showed that the 0.01 percent drops slowed down shortsightedness by around 50 percent.
The reason doctors have already been sluggish to make use of atropine to deal with myopia is that, in higher doses, it might possess some concerning unwanted effects such as pupil dilation and allergic conjunctivitis, which can cause light sensitivity and blurry vision when looking at objects up close.Though these symptoms were observed in the high dose drops being used by the kids during the study, those who used the 0.01 percent dose had pupil dilation of less than 1 mm, which minimised light sensitivity. The children also reported experiencing minimal near-vision loss after using the low-dose drops, and the researchers suggest that the benefits of the medication outweigh these risks.
Combined with other interventions, this treatment could become a great ally in preventing myopia from causing serious visual impairment in children worldwide,” said Tan.
That said, more study must be performed on the long-term security of the drops, especially on children. Seeing as around 9 percentage of the participants inside the low-dose group of the research did not react to the drops at all.
Further studies are occurring in Japan and Europe, and will hopefully give more details.